Probes Drive Valeant To Fewer Price-Based Transactions
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International Inc. on Oct. 19 said the "turmoil" over its practices of buying up companies with older drugs and raising their prices has driven the company to change its strategy to seek fewer transactions focused on what it called "mispriced products."